Macdonald M J, Gore S M, Cullen P M, Phillips C I
Br J Ophthalmol. 1977 May;61(5):345-8. doi: 10.1136/bjo.61.5.345.
The ocular hypotensive effect of single oral doses of (a) atenolol (50 mg), (b) acetazolamide (500 mg), (c) atenolol (50 mg) and acetazolamide (500 mg) in combination, and (d) vehicle (inert tablets) were compared in 8 patients with glaucoma. In this single-dose, double-masked trial the combination was observed as most effective in reducing ocular tension. Both the combination and atenolol performed markedly better than vehicle. That acetazolamide did not reduce ocular tension significantly more than vehicle is probably explained by relatively low initial ocular tensions. There was no evidence of interaction between atenolol and acetazolamide in this study. Acetazolamide probably remains the first-choice oral medication for glaucoma. It is cautiously suggested that beta-blocking drugs may have a future therapeutic role, but longer-term studies on larger numbers will be required to establish this.
在8例青光眼患者中比较了单次口服(a)阿替洛尔（50毫克）、(b)乙酰唑胺（500毫克）、(c)阿替洛尔（50毫克）与乙酰唑胺（500毫克）联合用药以及(d)赋形剂（惰性片剂）的降眼压效果。在这项单剂量双盲试验中，观察到联合用药降低眼压的效果最为显著。联合用药和阿替洛尔的效果均明显优于赋形剂。乙酰唑胺降低眼压的效果不比赋形剂显著更多，这可能是由于初始眼压相对较低。本研究中没有证据表明阿替洛尔与乙酰唑胺之间存在相互作用。乙酰唑胺可能仍是青光眼的首选口服药物。谨慎建议β受体阻滞剂可能具有未来的治疗作用，但需要对更多患者进行长期研究来证实这一点。
